Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector has agreed to acquire Vibalogics GmbH, a contract development and manufacturing organization focused on complex live biological products. Financial terms were not disclosed. Ampersand’s growth investment will be used to expand Vibalogics’ capabilities to meet rapidly growing industry demand for the development and manufacturing of complex viral products. “With the benefit of Ampersand as our partner, Vibalogics will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities. The partnership solidifies Vibalogics’ existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer and genetic disorders." Stefan Beyer, Ph.D., Vibalogics CEO.